VTGN News and Press, VistaGen Therapeutics Inc. From 12/21/22

VistaGen Therapeutics will acquire Pherin Pharmaceuticals , which is focused on neuropsychiatric and neuroendocrine conditions. Deal terms call for VistaGen ( NASDAQ: VTGN ) to pay with 12.4M shares of its common stock as well as some cash. Pherin's latest stage asset is PH94B, ...

Vistagen’s acquisition of Pherin will eliminate all future royalty and milestone payment obligations related to PH94B and PH10 and add three new pherine drug candidates to Vistagen’s pipeline Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical comp...

NEW YORK, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the presentations from its KCSA Mental Health Virtual Investor Conference held on...

NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, in partnership with KCSA Strategic Communications (“KCSA”), today announced the agenda for the upcoming KCSA Mental Health Virtual Investor Conference to be ...

These Penny Stocks Trading Mistakes Can Cost You Money New investors in the stock market often make mistakes when trading penny stocks. It’s important to understand the risks associated with this kind of investment and develop strategies for minimizing those risks. For that reason, con...

VistaGen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has received Fast Track designation from the U.S. Fo...

The Fast Track designation may expedite development of PH10 for treatment of major depressive disorder in adults Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and othe...

Vistagen to conduct small U.S. Phase 1 trial with newly optimized formulation of PH10 in Q1 2023 to confirm favorable safety profile from three previous clinical trials and to facilitate Phase 2B development of PH10 for major depressive disorder Vistagen , (NASDAQ: VTGN) a late clin...

VistaGen Therapeutics (NASDAQ: VTGN) , a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, has published findings of a preclinical study ...

Preclinical data in "gold standard" MPTP non-human primate model of Parkinson's disease show significant reduction of levodopa-induced dyskinesia by AV-101, while maintaining antiparkinsonian activity of levodopa Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceu...